UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 58

Sortiert nach

Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease

Brain (London, England : 1878), 2015-09, Vol.138 (Pt 9), p.2687-2700

2015

Volltextzugriff (PDF)

Pregabalin Add‐on Treatment: A Randomized, Double‐blind, Placebo‐controlled, Dose–Response Study in Adults with Partial Seizures

Epilepsia (Copenhagen), 2004-01, Vol.45 (1), p.20-27

2004

Volltextzugriff (PDF)

Pharmacokinetics, Safety, and Tolerability of SHP465 Mixed Amphetamine Salts After Administration of Multiple Daily Doses in Children Aged 4–5 Years with Attention-Deficit/Hyperactivity Disorder

CNS drugs, 2022-01, Vol.36 (1), p.71-81

2022

Volltextzugriff (PDF)

AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics

Journal of Alzheimer's disease, 2016-01, Vol.50 (4), p.1109

2016

Volltextzugriff (PDF)

AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's Disease

Journal of Alzheimer's disease, 2017-01, Vol.55 (3), p.1039

2017

Volltextzugriff (PDF)

BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid A[beta] Peptides

Journal of clinical pharmacology, 2017-11, Vol.57 (11), p.1460

2017

Volltextzugriff (PDF)

BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid Aβ Peptides

Journal of clinical pharmacology, 2017-11, Vol.57 (11), p.1460-1471

2017

Volltextzugriff (PDF)

Failure of Neuroprotection Despite Microglial Suppression by Delayed-Start Myeloperoxidase Inhibition in a Model of Advanced Multiple System Atrophy: Clinical Implications

Neurotoxicity research, 2015-10, Vol.28 (3), p.185-194

2015

Volltextzugriff (PDF)

Clinically Negligible Pharmacokinetic and Pharmacodynamic Interactions Between Lanabecestat and Dabigatran Etexilate, a Prototypical P‐gp Substrate

Journal of clinical pharmacology, 2020-05, Vol.60 (5), p.586-594

2020

Volltextzugriff (PDF)

PK/PD MODELING OF AZD3293, A NOVEL BACE1 INHIBITOR FOR ALZHEIMER’S DISEASE IN HEALTHY SUBJECTS AND PATIENTS WITH ALZHEIMER’S DISEASE

Alzheimer's & dementia, 2016-07, Vol.12 (7), p.P613-P613

2016

Volltextzugriff (PDF)

5.20 PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF SHP465 MIXED AMPHETAMINE SALTS AFTER MULTIPLE DAILY DOSES IN CHILDREN AGED 4-5 YEARS WITH ADHD

Journal of the American Academy of Child and Adolescent Psychiatry, 2020-10, Vol.59 (10), p.S155-S155

2020

Volltextzugriff (PDF)

Safety, tolerability, pharmacokinetics, and pharmacodynamic effects of naloxegol at peripheral and central nervous system receptors in healthy male subjects: A single ascending-dose study

Clinical pharmacology in drug development, 2015-11, Vol.4 (6), p.434-441

2015

Volltextzugriff (PDF)

Prophylactic efficacy of single dose pulmonary administration of amphotericin B inhalation powder in a guinea pig model of invasive pulmonary aspergillosis

Journal of antimicrobial chemotherapy, 2012-04, Vol.67 (4), p.970-976

2012

Volltextzugriff (PDF)

Clinical Bioavailability of the Novel BACE1 Inhibitor Lanabecestat (AZD3293): Assessment of Tablet Formulations Versus an Oral Solution and the Impact of Gastric pH on Pharmacokinetics

Clinical pharmacology in drug development, 2018-03, Vol.7 (3), p.233-243

2018

Volltextzugriff (PDF)

Effects of Organic Anion, Organic Cation, and Dipeptide Transport Inhibitors on Cefdinir in the Isolated Perfused Rat Kidney

Antimicrobial Agents and Chemotherapy, 2003-02, Vol.47 (2), p.689-696

2003

Volltextzugriff (PDF)

ASSESSMENT OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFECTS ON PLASMA AND CEREBROSPINAL FLUID AB PEPTIDES OF AZD3293, A NOVEL BACE1 INHIBITOR, IN HEALTHY JAPANESE ADULTS

Alzheimer's & dementia, 2016-07, Vol.12 (7), p.P608-P609

2016

Volltextzugriff (PDF)

Simultaneous quantitation of the BACE1 inhibitor AZD3293 and its metabolite AZ13569724 in human matrices by LC-MS/MS

Bioanalysis, 2017-05, Vol.9 (9), p.813-826

2017

Volltextzugriff (PDF)

Safety, tolerability, and pharmacokinetics of multiple ascending doses of naloxegol

Clinical pharmacology in drug development, 2015-11, Vol.4 (6), p.442-448

2015

Volltextzugriff (PDF)

A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma

Pharmaceutical research, 1993-02, Vol.10 (2), p.276-281

1993

Volltextzugriff (PDF)

Cross-reactivity of fosphenytoin in two human plasma phenytoin immunoassays

Clinical chemistry (Baltimore, Md.), 1998-07, Vol.44 (7), p.1474-1480

1998

Volltextzugriff (PDF)

P2‐013: PK/PD Modeling of AZD3293, a Novel Bace1 Inhibitor for Alzheimer’s Disease in Healthy Subjects and Patients with Alzheimer’s Disease

Alzheimer's & dementia, 2016-07, Vol.12 (7S_Part_12), p.P613-P613

2016

Volltextzugriff (PDF)

Clinical Experience With Fosphenytoin in Adults: Pharmacokinetics, Safety, and Efficacy

Journal of child neurology, 1998-10, Vol.13 (1_suppl), p.S15-S18

1998

Volltextzugriff (PDF)

Pharmacokinetics of Fosphenytoin in Patients with Hepatic or Renal Disease

Epilepsia (Copenhagen), 1999-06, Vol.40 (6), p.777-782

1999

Volltextzugriff (PDF)

P2‐002: Assessment of The Safety, Tolerability, Pharmacokinetics, and Effects on Plasma and Cerebrospinal Fluid AB Peptides of AZD3293, a Novel Bace1 Inhibitor, in Healthy Japanese Adults

Alzheimer's & dementia, 2016-07, Vol.12 (7S_Part_12), p.P608-P609

2016

Volltextzugriff (PDF)

Pharmacology and pharmacokinetics of fosphenytoin

Neurology, 1996-06, Vol.46 (6 Suppl 1), p.S3

1996

Volltextzugriff (PDF)

1 – 25 von 58

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(57)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(56)
Tagungsberichte
(2)

Sprache

Englisch
(58)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease

Pregabalin Add‐on Treatment: A Randomized, Double‐blind, Placebo‐controlled, Dose–Response Study in Adults with Partial Seizures

Pharmacokinetics, Safety, and Tolerability of SHP465 Mixed Amphetamine Salts After Administration of Multiple Daily Doses in Children Aged 4–5 Years with Attention-Deficit/Hyperactivity Disorder

AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics

AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's Disease

BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid A[beta] Peptides

BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid Aβ Peptides

Failure of Neuroprotection Despite Microglial Suppression by Delayed-Start Myeloperoxidase Inhibition in a Model of Advanced Multiple System Atrophy: Clinical Implications

Clinically Negligible Pharmacokinetic and Pharmacodynamic Interactions Between Lanabecestat and Dabigatran Etexilate, a Prototypical P‐gp Substrate

PK/PD MODELING OF AZD3293, A NOVEL BACE1 INHIBITOR FOR ALZHEIMER’S DISEASE IN HEALTHY SUBJECTS AND PATIENTS WITH ALZHEIMER’S DISEASE

5.20 PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF SHP465 MIXED AMPHETAMINE SALTS AFTER MULTIPLE DAILY DOSES IN CHILDREN AGED 4-5 YEARS WITH ADHD

Safety, tolerability, pharmacokinetics, and pharmacodynamic effects of naloxegol at peripheral and central nervous system receptors in healthy male subjects: A single ascending-dose study

Prophylactic efficacy of single dose pulmonary administration of amphotericin B inhalation powder in a guinea pig model of invasive pulmonary aspergillosis

Clinical Bioavailability of the Novel BACE1 Inhibitor Lanabecestat (AZD3293): Assessment of Tablet Formulations Versus an Oral Solution and the Impact of Gastric pH on Pharmacokinetics

Effects of Organic Anion, Organic Cation, and Dipeptide Transport Inhibitors on Cefdinir in the Isolated Perfused Rat Kidney

ASSESSMENT OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFECTS ON PLASMA AND CEREBROSPINAL FLUID AB PEPTIDES OF AZD3293, A NOVEL BACE1 INHIBITOR, IN HEALTHY JAPANESE ADULTS

Simultaneous quantitation of the BACE1 inhibitor AZD3293 and its metabolite AZ13569724 in human matrices by LC-MS/MS

Safety, tolerability, and pharmacokinetics of multiple ascending doses of naloxegol

A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma

Cross-reactivity of fosphenytoin in two human plasma phenytoin immunoassays

P2‐013: PK/PD Modeling of AZD3293, a Novel Bace1 Inhibitor for Alzheimer’s Disease in Healthy Subjects and Patients with Alzheimer’s Disease

Clinical Experience With Fosphenytoin in Adults: Pharmacokinetics, Safety, and Efficacy

Pharmacokinetics of Fosphenytoin in Patients with Hepatic or Renal Disease

P2‐002: Assessment of The Safety, Tolerability, Pharmacokinetics, and Effects on Plasma and Cerebrospinal Fluid AB Peptides of AZD3293, a Novel Bace1 Inhibitor, in Healthy Japanese Adults

Pharmacology and pharmacokinetics of fosphenytoin

Suchergebnisse filtern